Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Voyageur PharmaceuticalsVYYRF -2.04%17 EV-to-EBITDA is -5.94 as of Aug. 02, 2026. GuruFocus rates VYYRF with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 746 Drug Manufacturers companies, Voyageur Pharmaceuticals ranks worse than 134048.12% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Voyageur Pharmaceuticals's enterprise value is $16.34 Mil.
Voyageur Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in May. 2026 was $-2.75 Mil. Therefore, Voyageur Pharmaceuticals's EV-to-EBITDA for today is -5.94.
The historical rank and industry rank for Voyageur Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
VYYRF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.91 Med: 0 Max: 0
Current: -5.79
VYYRF's EV-to-EBITDA is ranked worse than 100% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.995
vs VYYRF: -5.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Voyageur Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Voyageur Pharmaceuticals's share price for today is $0.096.
Voyageur Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyageur Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Voyageur Pharmaceuticals's EV-to-EBITDA falls into.
Voyageur Pharmaceuticals's current Enterprise Value is $16.34 Mil.
Voyageur Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyageur Pharmaceuticals (VYYRF) has a EV-to-EBITDA of -5.94 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Voyageur Pharmaceuticals. According to the industry distribution chart, Voyageur Pharmaceuticals ranks #999999 out of 746 companies in the Drug Manufacturers industry.
Is Voyageur Pharmaceuticals' EV-to-EBITDA too high?
Voyageur Pharmaceuticals' current EV-to-EBITDA is -5.94. Based on the distribution chart, Voyageur Pharmaceuticals ranks #999999 out of 746 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Voyageur Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Voyageur Pharmaceuticals ranks #999999 out of 746 companies for EV-to-EBITDA. This places Voyageur Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.00, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Voyageur Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyageur Pharmaceuticals's current EV-to-EBITDA is -5.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current EV-to-EBITDA of -5.94. The current EV-to-EBITDA is -5.94. Voyageur Pharmaceuticals' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current EV-to-EBITDA is -5.94 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
17GF Score
Get the complete analysis for VYYRF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYYRF has been successfully added to your 
